Study of IBI362 for liver scarring from MASH
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your body mass index (BMI) must be 25 or higher.
- You must have a confirmed diagnosis of MASH with moderate to advanced liver scarring (stage F2 or F3) based on a recent liver biopsy.
- Your liver disease should not be caused by other conditions like hepatitis B or C, HIV, or certain other liver diseases.
- Your liver and overall health must meet specific safety criteria (such as not having severe liver failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This trial tests a new drug, IMM-H014, for a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). It looks at how well people tolerate the drug and how it works in the body. This might help if you have fat buildup in your liver along with other health issues like high blood pressure, diabetes, or high cholesterol.
This study tests a new drug called ALN-CIDEB for adults with MASH (a type of liver disease linked to metabolic health issues like obesity and diabetes). The drug aims to slow or reverse liver scarring (fibrosis) in people with moderate damage.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Hear when a new Metabolic Dysfunction-associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.